KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Gains from Investment Securities: 2009-2025

Historic Gains from Investment Securities for Biomarin Pharmaceutical (BMRN) over the last 13 years, with Sep 2025 value amounting to $2.2 million.

  • Biomarin Pharmaceutical's Gains from Investment Securities fell 63.19% to $2.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $58.2 million, marking a year-over-year decrease of 24.03%. This contributed to the annual value of $77.6 million for FY2024, which is 1.63% up from last year.
  • Latest data reveals that Biomarin Pharmaceutical reported Gains from Investment Securities of $2.2 million as of Q3 2025, which was down 82.32% from $12.3 million recorded in Q2 2025.
  • In the past 5 years, Biomarin Pharmaceutical's Gains from Investment Securities registered a high of $108.0 million during Q1 2022, and its lowest value of -$53.7 million during Q4 2022.
  • Over the past 3 years, Biomarin Pharmaceutical's median Gains from Investment Securities value was $12.3 million (recorded in 2025), while the average stood at $18.8 million.
  • Within the past 5 years, the most significant YoY rise in Biomarin Pharmaceutical's Gains from Investment Securities was 271.17% (2022), while the steepest drop was 4,001.02% (2022).
  • Over the past 5 years, Biomarin Pharmaceutical's Gains from Investment Securities (Quarterly) stood at $1.4 million in 2021, then tumbled by 4,001.02% to -$53.7 million in 2022, then skyrocketed by 107.30% to $3.9 million in 2023, then climbed by 25.23% to $4.9 million in 2024, then slumped by 63.19% to $2.2 million in 2025.
  • Its Gains from Investment Securities was $2.2 million in Q3 2025, compared to $12.3 million in Q2 2025 and $38.8 million in Q1 2025.